Business1 outlet
US-Based Axiom Seeks Hong Kong IPO to Tap China's Biotech Boom
Axiom Biosciences, a US-based biotechnology company, is considering listing on the Hong Kong Stock Exchange to access China's rapidly growing clinical development capabilities. This move is unusual for American biotech firms and signals the company's strategy to leverage Asia's robust research and development infrastructure.
Readers say
How does this story lean?
Outlet ratings above are Trace's curated source map. Vote here (same as on the home feed) — one vote per browser, changeable anytime. Rate individual outlets in the coverage list below.
How does this lean?
Comments
0No comments yet. Say what you noticed in the coverage.
Trending